



Press Release

Testosterone Cypionate Injection, USP, CIII

Contact:

Suzanne Collier
Marketing Communications
888 TEVA USA

Teva Introduces Testosterone Cypionate Injection, USP, CIII

Irvine, California, April 16, 2007 – Teva Pharmaceuticals is pleased to announce the introduction and availability of Testosterone Cypionate Injection, USP, CIII. This product is AO Rated to Depo[®]*-Testosterone Injection. Testosterone Cypionate Injection is available in 200 mg/mL-200 mg in 1 mL multiple dose glass vials, and 200 mg/mL-2000 mg in 10 mL multiple dose glass vials.

“Teva offers a broad range of quality health systems generics from a single source,” states Jonathan Zalk, Director of Marketing. “We are pleased to announce this latest addition to our growing line.”

Teva Pharmaceuticals, located in North Wales, Pennsylvania, is the leading pharmaceutical manufacturer for both new and total prescriptions.[‡] The company has an aggressive Research and Development effort and one of the best overall ANDA approval records in the industry.[‡]

* Depo[®] is a registered trademark of Upjohn Company.

‡ Data on file, Teva.

Please see accompanying prescribing information.